Publication | Open Access

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

NanomedicineUrologyPolymer-drug ConjugateMedicineTherapeutic NanomaterialsPhase Ii StudyPharmaceutical NanotechnologyTumor TargetingProstatic DiseaseOncologyRadiation OncologyNanocrystal® Dispersion